Merkel cell carcinoma: Clinical practice guidelines in oncology™

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 7, 2006, Pages 704-712

  Miller, Stanley J ^a   Alam, Murad ^b   Andersen, James ^c   Berg, Daniel ^d   Bichakjian, Christopher K ^e   Bowen, Glen ^f   Cheney, Richard T ^g   Glass, Frank ^h   Grekin, Roy C ⁱ   Grichnik, James M ^j   Johnson, Timothy M ^d   Kessinger, Anne ^k   Lee, Nancy Y ^l   Lessin, Stuart ^m   Lydiatt, Daniel D ^k   Margolis, Lawrence W ⁱ   Nehal, Kishwer S ^l   Nghiem, Paul ^m   Oseroff, Allan R ⁿ   Rosenberg, E William ^o   Shaha, Ashok R ^m   Siegle, Ronald J ^p   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c City of Hope Cancer Center   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j DUKE CANCER INSTITUTE   (United States)

^k NEBRASKA MEDICAL CENTER   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m FOX CHASE CANCER CENTER   (United States)

ⁿ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^o UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^p OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

Merkel cell carcinoma; NCCN Clinical Practice Guidelines; Neuroendocrine sarcoma; Nonmelanoma skin cancer; Sentinel lymph node biopsy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; TOPOTECAN;

ADJUVANT CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; HUMAN; LYMPH NODE DISSECTION; MELANOMA; MERKEL CELL TUMOR; METASTASIS; ONCOLOGY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE;

EID: 33747697824     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0060     Document Type: Review

References (47)

1. Poulsen M. Merkel-cell carcinoma of the skin. Lancet Oncol 2004;5:593-599.
2. Medina-Franco H, Urist MM, Fiveash J, et al. Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol 2001;8:204-208.
3. Lawenda BD, Thiringer JK, Foss RD, et al. Merkel cell carcinoma arising in the head and neck: optimizing therapy. Am J Clin Oncol 2001;24:35-42.
4. Gillenwater AM, Hessel AC, Morrison WH, et al. Merkel cell carcinoma of the head and neck. Effect of surgical excision and radiation on recurrence and survival. Arch Otolaryngol Head Neck Surg 2001;127:149-154.
5. Akhtar S, Oza KK, Wright J. Merkel cell carcinoma: report of 10 cases and review of the literature. J Am Acad Dermatol 2000;43:755-767.
6. Gollard R, Weber R, Kosty M, et al. Merkel cell carcinoma. Review of 22 cases with surgical, pathologic, and therapeutic considerations. Cancer 2000;88:1842-1851.
7. Allen PJ, Zhang ZF, Coit DG. Surgical management of merkel cell carcinoma. Ann Surg 1999;229:97-105.
8. Ott MJ, Tanabe KK, Gadd MA, et al. Multimodality management of merkel cell carcinoma. Arch Surg 1999;134:388-393.
9. Gruber S, Wilson L. Merkel cell carcinoma. In: Miller SJ, Maloney ME, eds. Cutaneous Oncology: Pathophysiology, Diagnosis, and Management. Maiden, MA: Blackwell Science; 1998:710-721.
10. Wong KC, Zuletta F, Clarke SJ, et al. Clinical management and treatment outcomes of merkel cell carcinoma. Aust NZ J Surg 1998;68:354-358.
11. Skelton HG, Smith KJ, Hitchcock CL, et al. Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol 1997;37:734-739.
12. Kokoska ER, Kokoska MS, Collins BT, et al. Early aggressive treatment for merkel cell carcinoma improves outcome. Am J Surg 1997;174:688-693.
13. O'Connor WJ, Roenigk RK, Brodland DG. Merkel cell carcinoma. Comparison of Mohs micrographic surgery and wide excision in eighty-six patients. Dermatol Surg 1997;23:929-933.
14. Haag ML, Glass LF, Fenske NA. Merkel cell carcinoma. Diagnosis and treatment. Dermatol Surg 1995;21:669-683.
15. Ratner D, Nelson BR, Brown MD, et al. Merkel cell carcinoma. J Am Acad Dermatol 1993;29:143-156.
16. Pitale M, Sessions RB, Husain S. An analysis of prognostic factors in cutaneous neuroendocrine carcinoma. Laryngoscope 1992;102:244-249.
17. Hitchcock CL, Bland KI, Laney RG, et al. Neuroendocrine (merkel cell) carcinoma of the skin. Its natural history, diagnosis, and treatment. Ann Surg 1988;207:201-207.
18. Herbst A, Haynes HA, Nghiem P. The standard of care for Merkel cell carcinoma should include adjuvant radiation and lymph node surgery (letter). J Am Acad Dermatol 2002;46:640-641.
19. Allen PJ, Bowne WB, Jaques DP, et al. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 2005;23:2300-2309.
20. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol 2003;49:832-841.
21. Miller SJ. NCCN practice guidelines for nonmelanoma skin cancer. Oncol 1999;13:529-549.
22. Cheuk W, Kwan MY, Suster S, et al. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med 2001;125:228-231.
23. Hanly AJ, Elgart GW, Jorda M, et al. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates merkel cell carcinoma from small cell carcinoma of lung. J Cutan Pathol 2000;27:118-120.
24. Nicholson SA, McDermott MB, Swanson PE, Wick MR. CD99 and cytokeratin-20 in small-cell and basaloid tumors of skin. Appl Immunohistochem Mol Morphol 2000;8:37-41.
25. Scott MP, Helm KF. Cytokeratin 20: a marker for diagnosing merkel cell carcinoma. Am J Dermpathol 1999;21:16-20.
26. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual, 6th ed. New York, Berlin, Heidelberg: AJCC Springer-Verlag; 2002:203-204.
27. Pennington BE, Leffell DJ. Mohs micrographic surgery: established uses and emerging trends. Oncology 2005;19:1165-1171.
28. Mehrany K, Otley CC, Weenig RH, et al. A meta-analysis of the prognostic significance of sentinel lymph node status in merkel cell carcinoma. Dermatol Surg 2002;28:113-117.
29. Hill ADK, Brady MS, Coit DG. Intraoperative lymphatic mapping and sentinel lymph node biopsy for merkel cell carcinoma. Br J Surg 1999;86:518-521.
30. Messina JL, Reintgen DS, Cruse CW, et al. Selective lymphadenectomy in patients with merkel cell (cutaneous neuroendocrine) carcinoma. Ann Surg Oncol 1997;4:389-395.
31. Ames SE, Krag DN, Brady MS. Radiolocalization of the sentinel lymph node in Merkel cell carcinoma: a clinical analysis of seven cases. J Surg Oncol 1998;67:251-254.
32. Su LD, Lowe L, Bradford CR, et al. Immunostaining for cytokeratin 20 improves detection of micrometastatic merkel cell carcinoma in sentinel lymph nodes. J Am Acad Dermatol 2002;46:661-666.
33. Schmalbach CE, Lowe L, Teknos TN, et al. Reliability of sentinel lymph node biopsy for regional staging of head and neck Merkel cell carcinoma. Arch Otolaryngol Head Neck Surg 2005;131:610-614.
34. Bischof M, van Kampen M, Huber P, et al. Merkel cell carcinoma: the role of radiation therapy in general management. Strahlenther Onkol 1999;175:611-615.
35. Wilson LD, Gruber SB. Merkel cell carcinoma and the controversial role of adjuvant radiation therapy: clinical choices in the absence of statistical evidence. J Am Acad Dermatol 2004;50:435-437; discussion 437-438.
36. Veness MJ, Morgan GJ, Gebski V. Adjuvant locoregional radiotherapy as best practice in patients with Merkel cell carcinoma of the head and neck. Head Neck 2005;27:208-216.
37. Veness MJ, et al. Merkel cell carcinoma: improved outcome with adjuvant radiotherapy. Aust N Z J Surg 2005;75:275-281.
38. Eng TY, Boersma MGK, Fuller CD, et al. Treatment of Merkel cell carcinoma. Am J Clin Oncology 2004;27:510-515.
39. Tai PT, Yu E, Winquist E, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 2000;18:2493-2499.
40. Voog E, Biron P, Martin JP, et al. Chemotherapy for patients with locally advanced or metastatic merkel cell carcinoma. Cancer 1999;85:2589-2595.
41. Poulsen M, Rischin D, Walpole E, et al. High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study-TROG 96:07. J Clin Oncol 2003;21:4371-4376.
42. Poulsen MG, Rischin D, Porter I, et al. Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin? Int J Radiat Oncol Biol Phys 2006;64:114-119.
43. Sihto H, Sarlomo-Rikala M, Tynninen O, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 2005;23:49-57.
44. Kondapalli L, Soltani K, Lacouture ME. The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. J Am Acad Dermatol 2005;53:291-302.
45. Feinmesser M, Halpern M, Kaganovsky E, et al. C-KIT expression in primary and metastatic Merkel cell carcinoma. Am J Dermatopathol 2004;26:458-462.
46. Imatinib mesylate in treating patients with metastatic or unresectable Merkel cell cancer: sponsored by Southwest Oncology Group, National Cancer Institute (NCI) and Eastern Cooperative Oncology Group. Available at http://www.ClinicalTrials.gov, identifier: NCT00068783. Accessed May 15, 2006.
47. Oblimersen in treating patients with metastatic or recurrent Merkel cell carcinoma: Memorial Sloan-Kettering Cancer Center and National Cancer Institute (NCI). Available at http://www.ClinicalTrials.gov, identifier: NCT00079131. Accessed May 15, 2006.